

A Partnership Including
Professional Corporations
600 13th Street, N.W.
Washington, D.C. 20005-3096
202-756-8000
Facsimile 202-756-8087
<http://www.mwe.com>

2636 '03 MAY 20 A9:07

Boston
Chicago
London
Los Angeles
Miami
Moscow
New York
Orange County
St. Petersburg
Silicon Valley
Vilnius
Washington, D.C.

MCDERMOTT, WILL & EMERY

May 19, 2003

VIA FEDERAL EXPRESS

Dockets Management Branch
Food and Drug Administration
Department of Health and Human Services
5630 Fishers Lane, Room 1061, HFA-305
Rockville, MD 20852


Re: Notice of QT5, Inc.'s Intent to File Comments
Concerning Citizen Petition - Docket No. 01P-0572
and Supplemental Citizen Petition - Docket No. 01P-0573

Dear Sir/Madam:

I am writing on behalf of our client QT5, Inc. with respect to the above referenced Citizen Petition and Supplemental Citizen Petition. In conjunction with the company, outside homeopathic pharmaceutical experts and counsel, we have evaluated the above referenced Citizen Petition and Supplement concerning QT5, Inc.'s homeopathic drug product containing Nicotinum, NICOWater™ and are in the process of preparing formal comments for submission to the docket. These formal comments will demonstrate and support the conclusion that the Citizen Petition and Supplemental Citizen Petition are without merit and should therefore be denied. Accordingly, we trust that the Agency will not take any action or issue a response to the Petitioners until such comments are received.

We will submit substantive comments on the Citizen Petition and Supplemental Citizen Petition within the next 30 days.

Sincerely yours,



David L. Rosen, R.Ph., J.D.

cc: QT5, Inc.
Mr. Steve Reder

Michael Landa, Esq.
FDA, Office of the Chief Counsel

OIP-0573

Let 1